Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19

Stock Information for Bellerophon Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.